Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium
- 30 September 2009
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 45 (13), 2342-2351
- https://doi.org/10.1016/j.ejca.2009.03.007
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and AdultsClinical Cancer Research, 2008
- Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group StudyJournal of Clinical Oncology, 2008
- Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report1Neuro-Oncology, 2007
- Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal TumorsClinical Cancer Research, 2006
- Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08Clinical Cancer Research, 2006
- Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2005
- Immunohistochemical analysis of desmoid tumoursJournal of Clinical Pathology, 2005
- Rare expression of KIT (CD117) in lymphomas: a tissue microarray study of 1166 casesHistopathology, 2004
- Expression of C-kit in Ewing Family of Tumors: A Comparison of Different Immunohistochemical ProtocolsPediatric and Developmental Pathology, 2004
- Treatment of hypereosinophilic syndrome with imatinib mesilateThe Lancet, 2002